In previous clinical studies, PTX3 was found to be increased in other tumors such as liposarcomas [31], glioma [32], lung [20] and prostate cancer [33] compared to paired healthy controls [20, 33] or to benign hyperplasia [33]. This evidence concerns the gene PTX3 and prostate carcinoma.